logo

EbookBell.com

Most ebook files are in PDF format, so you can easily read them using various software such as Foxit Reader or directly on the Google Chrome browser.
Some ebook files are released by publishers in other formats such as .awz, .mobi, .epub, .fb2, etc. You may need to install specific software to read these formats on mobile/PC, such as Calibre.

Please read the tutorial at this link:  https://ebookbell.com/faq 


We offer FREE conversion to the popular formats you request; however, this may take some time. Therefore, right after payment, please email us, and we will try to provide the service as quickly as possible.


For some exceptional file formats or broken links (if any), please refrain from opening any disputes. Instead, email us first, and we will try to assist within a maximum of 6 hours.

EbookBell Team

Cancer Immunotherapies Solid Tumors And Hematologic Malignancies Priya Hays

  • SKU: BELL-43105604
Cancer Immunotherapies Solid Tumors And Hematologic Malignancies Priya Hays
$ 31.00 $ 45.00 (-31%)

4.0

6 reviews

Cancer Immunotherapies Solid Tumors And Hematologic Malignancies Priya Hays instant download after payment.

Publisher: Springer
File Extension: PDF
File size: 5.83 MB
Pages: 643
Author: Priya Hays
ISBN: 9783030963750, 3030963756
Language: English
Year: 2022

Product desciption

Cancer Immunotherapies Solid Tumors And Hematologic Malignancies Priya Hays by Priya Hays 9783030963750, 3030963756 instant download after payment.

This book presents the clinical scope of cancer immunotherapeutic agents for solid tumors and hematological malignancies, elaborates on the scientific details of their modes of action, and presents the impact of these agents on oncology, patients and the broader healthcare system. At present, cancer immunotherapies fall broadly into three categories: immune checkpoint inhibitors (ICIs), adoptive T cell therapies, and cancer vaccines which have distinct mechanisms of action. Immune checkpoint inhibitors rely upon disrupting tumor antigen recognition as self by the immune system through inhibition of checkpoint molecules. Adoptive T cell therapies involve the engineering of T cells ex vivo to target and destroy tumor cells. The first part of this book will provide an overview of the discovery and mechanistic details of the technology. The second part will be devoted to elaborating on the clinical outcomes, successes and limitations for specific tumor subtypes, which includes both solid tumors and hematological malignances for both pediatric and adult populations. As such, the book offers a valuable resource for oncologists, hematologists, and all those seeking an up-to-date overview of cancer immunotherapies.

Related Products